EUVIMEDEUVIMED entdecken
Open Access

PD-L2 Landscape and Correlation With Outcome: An Immunomic Analysis

Anannya Patwari, Daisuke Nishizaki, Taylor Jensen, Paul DePietro, Sarabjot Pabla, Shumei Kato, Razelle Kurzrock

JCO Oncology Advances · 2026-01 · 3 (1)

DOI: 10.1200/oa-25-00151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Advances, 2026-01. Verfasst von Anannya Patwari und 6 weiteren Autor:innen. Beteiligte Einrichtung: MCW Cancer Center and Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin, Milwaukee, WI, United States. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE PD-L1 and PD-L2 are inhibitory ligands that interact with PD-1 receptors, enabling immune escape. Although PD-L1 has been extensively studied, much less is known about PD-L2. PD-L2 expression could lead to incomplete blockade of the PD-1 axis by anti–PD-L1 agents and also influence the activity of anti–PD-1 agents. METHODS We analyzed PD-L2 transcriptomic expression in a pan-cancer cohort (N = 514; 489 patients with advanced/metastatic disease and clinical correlates available) for associations with immunomodulatory variables and outcome. RESULTS The most common tumors were colorectal (27% [140 of 514]), pancreatic (11% [55 of 514]), and breast cancer (9.5% [49 of 514]). High PD-L2 expression (≥75th RNA percentile rank) occurred in 19.5% (100 of 514) of patients; PD-L2 expression varied across and within tumor types. High PD-L2 independently/significantly correlated with high PD-L1, PD-1, CD4, and T-cell immunoglobulin and mucin-containing protein 3 (TIM-3) RNA levels (both as dichotomized and linear variables), high tumor mutational burden (TMB; ≥10 mutations/Mb), and a breast cancer diagnosis. In 217 patients who received immune checkpoint blockade (mainly anti–PD-1-based regimens), high versus moderate/low PD-L2 predicted longer overall survival (OS) (but not progression-free survival) in univariate analysis (median, 1.88 years [95% CI, 1.37 to not estimable] versus 1.21 years [95% CI, 0.95 to 1.54]; P = .02). In 272 patients who never received immunotherapy, high PD-L2 expression was not prognostic for OS. CONCLUSION High PD-L2 transcripts were more common in breast cancer and associated with high expression of other immune-relevant factors: PD-L1, PD-1, CD4, and TIM-3, and with TMB ≥10 mutations/Mb. High PD-L2 levels correlated with longer OS in immunotherapy-treated patients.

Schlagwörter

Stichwörter der Autor:innen

Immune Checkpoint InhibitorsImmunotherapyNeoplasmsPrecision MedicineProgrammed Cell Death 1 Ligand 2 Protein

Autor:innen und Institutionen

  • MCW Cancer Center and Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin, Milwaukee, WI, United States.
  • Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, CA, United States.
  • Labcorp, Buffalo, NY, United States.
  • WIN consortium, Paris, France.

Förderung

  • NCI NIH HHS

Zitieren

APA

Patwari, A., Nishizaki, D., Jensen, T., DePietro, P., Pabla, S., Kato, S., & Kurzrock, R. (2026). PD-L2 Landscape and Correlation With Outcome: An Immunomic Analysis. JCO Oncology Advances, 3(1). https://doi.org/10.1200/oa-25-00151

Vancouver

Patwari A, Nishizaki D, Jensen T, DePietro P, Pabla S, Kato S, et al. PD-L2 Landscape and Correlation With Outcome: An Immunomic Analysis. JCO Oncology Advances. 2026;3(1). doi:10.1200/oa-25-00151

BibTeX
@article{Patwari2026,
  author = {Patwari, Anannya and Nishizaki, Daisuke and Jensen, Taylor and DePietro, Paul and Pabla, Sarabjot and Kato, Shumei and Kurzrock, Razelle},
  title = {PD-L2 Landscape and Correlation With Outcome: An Immunomic Analysis},
  journal = {JCO Oncology Advances},
  year = {2026},
  volume = {3},
  number = {1},
  doi = {10.1200/oa-25-00151}
}
Kostenlos starten →